Topical corticosteroid concerns in dermatological outpatients in Saudi Arabia

Abstract

Background and Aims: Topical corticosteroids (TCS) are commonly prescribed by dermatologists for a wide range of inflammatory skin conditions. However, concerns that patients have regarding the use of TCS can greatly affect their adherence to treatment. Adherence to prescribed treatments and the challenges faced by non-adherent individuals are critical areas of focus. This research evaluates knowledge gaps and concerns regarding TCS use in dermatology outpatient settings in Saudi Arabia, aiming to reduce misunderstandings, improve treatment recommendations, and optimize both safety and efficacy in dermatological practice. Methods: A total of 383 patients with various skin conditions answered an online questionnaire on the concerns related to steroid containing cream/ointment use. The data were statistically analyzed using the (SPSS) software. Chi-square test was used to determine the association between patients characteristics and TCS-related concerns. Results: Among participants, 53% reported being prescribed steroid creams/ointments, with 15.1% for their children. More than half 56.7% were concerned about their health while using topical corticosteroids. The leading concerns were skin thinning and systemic effects. The most frequent source of TCS concerns were negative reports by the internet and other media. Significantly, concern about health was higher among those with female children, those with university education, and nonmedical workers (p<0.05). Conclusion: TCS concerns are common among dermatological patients. Increasing patients’ knowledge and awareness may reduce TCS concerns.

References

1. 1.Mehta AB, Nadkarni NJ, Patil SP, Godse KV, Gautam M, Agarwal S. Topical corticosteroids in dermatology. Indian J Dermatol Venereol Majmaah Journal of Health Sciences,Vol.14, Issue1, January-2026,Rajabi-1447 91 Topical corticosteroid concernsindermatologicaloutpatientsinSaudiArabia Leprol. 2016;82(4):371–378. doi: 10.4103/0378- 6323.178903. doi:10.4103/0378-
2. 2.Egeberg A, Thyssen JP. Topical corticosteroids in the era of new topical therapies: Balancing efficacy and safety forlong-termuse.JEurAcadDermatol Venereol. 2024;38(7):1236–1237. doi: 10.1111/jdv.20041. doi:10.1111/jdv.20041
3. 3.Lovrić I, Tomić I, Tomić I, Zeljko I, Bevanda M, Mandić M, Lovrić S, Šimić D. Inappropriate use of topical corticosteroids in dermatology outpatients. Psychiatria Danubina. 2021;33(Suppl 10):71–75.
4. 4.CoondooA,PhiskeM,VermaS,Lahiri K. Side-effects of topical steroids: A long overdue revisit. Indian Dermatol Online J. 2014;5(4):416–425. doi: 10.4103/22295178.142483. doi:10.4103/22295178.142483
5. 5.Contento M, Cline A, Russo M. Steroid phobia: A review of prevalence, risk factors, and interventions. Am J Clin Dermatol. 2021;22(6):837–851. doi: 10.1007/s40257-02100623-6. doi:10.1007/s40257-02100623-6
6. 6.Callen J, Chamlin S, Eichenfield LF, Ellis C, Girardi M, Goldfarb M, Hanifin J,Lee P,Margolis D,Paller AS, Piacquadio D, Peterson W, Kaulback K, Fennerty M, Wintroub BU. A systematicreviewofthesafetyoftopical therapies for atopic dermatitis. Br J Dermatol. 2007;156(2):203– 221. doi: 10.1111/j.1365-2133.2006.07538.x. doi:10.1111/j.1365-2133.2006.07538.x
7. 7.Kew CH, Ahmad Basir KF, Low DW, Loh KC. Breaking through the steroid stigma: A singlecentre study on topical corticosteroid perception and adherence in dermatology patients and caregivers. Med J Malaysia. 2023;78(4):437–444.
8. 8.MoretL,AnthoineE,Aubert-Wastiaux H, Le Rhun A, Leux C, Mazereeuw- Hautier J, Stalder JF, Barbarot S. TOPICOP©: A new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parents.PLoSOne.2013;8(10):e76493. doi: 10.1371/journal.pone.0076493. doi:10.1371/journal.pone.0076493